2023 - Research.com Best Scientist Award
2023 - Research.com Medicine in Switzerland Leader Award
2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in Switzerland Leader Award
Member of the Association of American Physicians
His main research concerns Prostate cancer, Cancer research, Cancer, Prostate and Pathology. Prostate cancer is the subject of his research, which falls under Internal medicine. The study incorporates disciplines such as Endocrinology and Oncology in addition to Internal medicine.
The concepts of his Cancer research study are interwoven with issues in Bioinformatics, Metastasis, LNCaP, Androgen receptor and Adenocarcinoma. His work investigates the relationship between Cancer and topics such as Immunology that intersect with problems in Watchful waiting. His Prostate research includes elements of Immunohistochemistry, Tissue microarray, DNA methylation and Cancer biomarkers.
His primary scientific interests are in Prostate cancer, Cancer research, Cancer, Internal medicine and Pathology. His research in Prostate cancer tackles topics such as Prostate which are related to areas like Adenocarcinoma. His studies in Cancer research integrate themes in fields like Carcinogenesis, Gene, Chromoplexy, Metastasis and LNCaP.
Mark A. Rubin has included themes like SPOP, Computational biology, PTEN and Bioinformatics in his Cancer study. The various areas that Mark A. Rubin examines in his Internal medicine study include Endocrinology and Oncology. Pathology connects with themes related to Fluorescence in situ hybridization in his study.
Mark A. Rubin focuses on Prostate cancer, Cancer research, Cancer, Internal medicine and Oncology. His studies deal with areas such as Carcinogenesis, Prostate, SPOP and PTEN as well as Prostate cancer. His research integrates issues of PI3K/AKT/mTOR pathway and Disease in his study of Prostate.
His Cancer research research includes themes of Lineage, Transcriptome, Organoid, Androgen and Epigenetics. His research in Cancer intersects with topics in Precision medicine, Clinical trial, Computational biology and Gene. His Oncology research is multidisciplinary, incorporating perspectives in Biopsy, Cancer biomarkers, Personalized medicine and MEDLINE.
His main research concerns Prostate cancer, Cancer research, Internal medicine, Oncology and Cancer. His Prostate cancer study combines topics from a wide range of disciplines, such as Transcriptome, Prostate, PTEN and Cancer biomarkers. His Cancer research study integrates concerns from other disciplines, such as Lineage, Carcinogenesis, Phenotype, Mutation and Transcription factor.
His work in Internal medicine covers topics such as Endocrinology which are related to areas like PI3K/AKT/mTOR pathway. His Oncology study incorporates themes from Clinical trial and Gene mutation. The Cancer study combines topics in areas such as Exome sequencing, Immunology, SPOP, Gene and Computational biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
S.A. Tomlins;D.R. Rhodes;S. Perner;S.M. Dhanasekaran.
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler.
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei.
The polycomb group protein EZH2 is involved in progression of prostate cancer
Sooryanarayana Varambally;Saravana M. Dhanasekaran;Ming Zhou;Terrence R. Barrette.
Integrative clinical genomics of advanced prostate cancer
Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz.
Delineation of prognostic biomarkers in prostate cancer
Saravana M. Dhanasekaran;Terrence R. Barrette;Debashis Ghosh;Rajal Shah.
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse;Jaeil Ahn;Rehan Akbani;Adrian Ally.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo;Suzanne Carreira;Shahneen Sandhu;Susana Miranda.
The New England Journal of Medicine (2015)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
Celina G. Kleer;Qi Cao;Sooryanarayana Varambally;Ronglai Shen.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M Frampton;Alex Fichtenholtz;Geoff A Otto;Kai Wang.
Nature Biotechnology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: